Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Efficacy and Cost-effectiveness of Malaria Prevention in Pregnancy in an Area of Low and Unstable Transmission in Kabale, Uganda: Use of Intermittent Preventive Treatment and Insecticide-treated Nets.
Brief Summary: The purpose of this study is to compare the efficacy and cost-effectiveness of three alternative strategies for the prevention of malaria during pregnancy in an epidemic-prone area of low transmission in the East African Highlands.

The strategies being compared are:

* intermittent preventive treatment with sulfadoxine-pyrimethamine (IPT-SP)
* an insecticide treated net (ITN), and
* intermittent preventive treatment with SP plus an ITN

In addition to the main individually-randomised trial, outcome data was subsequently also gathered on pregnant women whose houses where sprayed with indoor residual insecticides (IRS) as part of a non-randomised district-wide control programme to compare the impact of IRS with the three intervention arms.


Options:
A: Inclusion Criteria:

* Signed informed consent
* Age \>= 15 years
* Ultrasound confirmed pregnancy
* Quickening
* Foetal age 14-26 gestation weeks
* Maternal availability for follow-up during the entire study period

Exclusion Criteria:

* Known maternal tuberculosis, diabetes, kidney disease or liver disease
* Any severe acute illness warranting hospital referral at enrollment visit
* Mental disorder that may affect comprehension of the study or success of follow-up
* Twin pregnancy
* Pregnancy complications evident at enrollment visit (moderate to severe oedema, blood hemoglobin \[Hb\] concentration \< 50 g/l, systolic blood pressure \[BP\] \> 160 mmHg or diastolic BP \> 100 mmHg)
* Prior receipt of azithromycin during this pregnancy
* Receipt of sulfadoxine and pyrimethamine within 28 days of enrollment
* Known allergy to drugs containing sulfonamides, macrolides or pyrimethamine
* History of anaphylaxis
* History of any serious allergic reaction to any substance, requiring emergency medical care
* Concurrent participation in any other clinical trial
B: Inclusion Criteria:

* First or second pregnancy
* Greater than 16 weeks gestation
* Less than 28 weeks gestation
* Consent for HIV testing

Exclusion Criteria:

* Less than 15 years old
C: Inclusion Criteria:

* Pregnant women whose pregnancies are at \<27 weeks gestation at first antenatal booking
* Permanent resident in study area
* Informed consent

Exclusion Criteria:

* Late presentation: pregnancies more than 26 weeks gestation at first antenatal booking
* Severe anaemia (Hb\<70g/L) on enrolment
* Previous reaction to a sulfa-drug (e.g. sulphadoxine-pyrimethamine, septrin)
* History of severe skin reaction to any drug
* Current (or history) of severe disease (e.g. hepatitis, jaundice, TB, AIDS)

Withdrawal Criteria:

* Withdrawal of consent
* Women developing severe anaemia (Hb\<70g/L)during pregnancy
D: Inclusion Criteria:

* Pregnant women with gestation between 18-32weeks,
* willing to give written consent to take part in the study
* Resident in the study area and available for follow-up.

Exclusion Criteria:

* Presentation with clinical symptoms of malaria (this would not affect subsequent enrollment at a later date),
* Known allergies or reactions to study drugs,
* Medical conditions needing hospital admission.

Answer: C